Application of data-intelligence algorithms for modeling the compaction performance of new pharmaceutical excipients

Garba M Khalid,Abdullahi G Usman

doi:10.1186/s43094-021-00183-w

Abstract

BackgroundPharmaceutical excipient development is an extensive process requiring a series of pre-formulation studies to evaluate their performance. The present study compares the conventional compaction and compression pre-formulation studies with artificial intelligence (AI) modeling to predict the performances of thermally and chemically modified starches obtained from Livingstone potato.ResultsThe native starch was modified by three methods, and we obtained the following starches; pregelatinized starch (PS), ethanol dehydrated pregelatinized starch (ES), and acid hydrolyzed starch (AS). Microcrystalline cellulose (Avicel® PH101) was employed as a reference since its use in tablet direct compression has been established. The role of compaction pressure on the degree of volume reduction of the tablets was studied using Kawakita and Heckel models which highlighted that when the starch is modified by pregelatinization followed by ethanol dehydration, and/and or acid hydrolysis modification, a directly compressible starch can be obtained that can plastically deform. The data-intelligence results indicated the reliability of the AI-based models over the linear models. Hence, the comparative results demonstrated that the Adaptive neuro-fuzzy inference system (ANFIS) outperformed the other two models in modeling the performance of all of the four excipients with considerable performance accuracy.ConclusionThe compressibility indices have shown matching characteristics of AS and ES to Avicel® PH101 in terms of direct compressibility potential than PS. Moreover, the data intelligence modeling demonstrates the reliability and satisfactory of ANFIS as a hybrid model over the other two models with increased performance skills in modeling the compaction properties of these novel pharmaceutical excipients.

Highlights

Pharmaceutical excipient development is an extensive process requiring a series of pre-formulation studies to evaluate their performance
Modifications of the native starch made by acid hydrolysis (AS) and pregelatinization followed by ethanol dehydration (ES) gave rise to good table excipients that can be used for direct compression tablet formulations based on their compaction and compressibility characteristics
This work employed the application of various models, namely two artificial intelligence-based models (ANFIS and Artificial neural networks (ANN)) and a linear model (MLR) for modeling the performance of three novel pharmaceutical excipients with one standard (Avicel® Microcrystalline cellulose (PH101)) based on their compact tablet densities as well as their degrees of volume reduction

Summary

Introduction

Pharmaceutical excipient development is an extensive process requiring a series of pre-formulation studies to evaluate their performance. To ensure safety and qualification for use in pharmaceuticals, manufacturers of pharmaceutical excipients must ensure the absence of intrinsic toxicity of excipients, and materials for excipients development are chosen from pharmaco-toxicologically inert substances [1, 2]. To achieve these goals, many regulatory agencies across the globe such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Japanese Ministry of Health, Labour and Welfare have set guidelines to guarantee the safety of excipients used by the pharmaceutical industries [1]

Objectives

Methods

Results

Discussion

Conclusion